| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | OSTL; IBRDC1; C6orf172; dJ84N20.1 |
| WB Predicted band size | 59 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human RNF217 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于RNF217抗体的3篇参考文献，按文献名称、作者和摘要内容概括整理：
1. **文献名称**: *RNF217 regulates iron homeostasis through its E3 ubiquitin ligase activity*
**作者**: Zhang Y, et al.
**摘要**: 本研究揭示了RNF217通过泛素化调控铁转运蛋白FPN1的降解，影响细胞内铁稳态。实验中采用RNF217抗体进行免疫共沉淀(Co-IP)和免疫荧光染色，证实其在铁代谢中的关键作用，为贫血相关疾病提供了潜在治疗靶点。
2. **文献名称**: *RNF217 promotes hepatocellular carcinoma progression by stabilizing oncogenic c-Myc protein*
**作者**: Li Q, et al.
**摘要**: 研究发现RNF217在肝癌中高表达，通过抑制c-Myc蛋白的泛素化降解促进肿瘤生长。利用RNF217抗体进行Western blot和免疫组化分析，显示其与患者预后不良显著相关，提示RNF217可作为肝癌诊断标志物。
3. **文献名称**: *RNF217 interacts with AMPK and regulates lipid metabolism in adipocytes*
**作者**: Wang H, et al.
**摘要**: 该文报道RNF217与AMPK复合物结合，调控脂肪细胞脂质代谢通路。通过RNF217抗体的敲低实验及蛋白质互作分析，发现其缺失导致AMPK活性下降，加剧肥胖相关代谢紊乱，为代谢综合征机制研究提供新视角。
4. **文献名称**: *RNF217-mediated ubiquitination of TLR4 in macrophages promotes inflammatory response*
**作者**: Chen L, et al.
**摘要**: 研究证明RNF217通过泛素化修饰TLR4受体，增强巨噬细胞炎症信号传导。使用RNF217抗体的功能阻断实验显示，抑制RNF217可减轻脓毒症模型中的过度炎症反应，提示其作为炎症性疾病干预靶点的潜力。
注：上述文献名为虚拟示例，实际引用需根据真实发表论文调整。建议通过PubMed或Web of Science以“RNF217 antibody”或“RNF217 function”为关键词检索最新研究。
The RNF217 antibody is a research tool designed to detect and study the Ring Finger Protein 217 (RNF217), an E3 ubiquitin ligase involved in cellular processes such as protein degradation, lipid metabolism, and signaling regulation. RNF217 contains a conserved RING domain, enabling its role in ubiquitination—a post-translational modification that tags proteins for proteasomal degradation or functional modulation. It has garnered attention for its association with metabolic and cardiovascular diseases, particularly through its interaction with lipid-regulating pathways. Studies link RNF217 to cholesterol homeostasis by promoting the degradation of LDLR (low-density lipoprotein receptor), influencing plasma cholesterol levels and atherosclerosis development.
Additionally, RNF217 is implicated in cancer, where its dysregulation may affect tumor progression, apoptosis, and drug resistance. Its overexpression has been observed in certain malignancies, suggesting potential as a biomarker or therapeutic target. In neurological contexts, RNF217 interacts with proteins linked to neurodegenerative disorders like Alzheimer’s disease, though its precise role remains under investigation.
The RNF217 antibody is widely used in techniques such as Western blotting, immunohistochemistry, and immunoprecipitation to analyze protein expression, localization, and molecular interactions. Researchers utilize it to explore RNF217's physiological and pathological mechanisms, aiding in the development of targeted therapies for related diseases. Validation of antibody specificity remains critical, given the structural similarities among E3 ligases.
×
